A Digital Transformation: Mary Kay Inc. Launches Immersive Virtual Experience Platform Suite 13TM
15.4.2021 16:03:00 EEST | Business Wire | Press release
Global beauty brand Mary Kay Inc. and its Mary Kay Global Design Studio present Suite 13TM, an innovative virtual beauty experience that leverages the use of virtual reality to digitize Mary Kay's first virtual pop-up showroom. Designed with the latest virtual reality technology, the new Suite 13TM offers Mary Kay Independent Beauty Consultants and their customers a 360-degree, 3D beauty experience where users can virtually browse the beauty brand’s portfolio of skin care as well as explore the company and its founder Mary Kay Ash’s history.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005306/en/
The new Suite 13™ offers Mary Kay Independent Beauty Consultants and their customers a 360-degree, 3D beauty experience. (Photo: Mary Kay Inc.)
The new Suite 13TM invites users to tour through virtual “rooms”. Upon entering the “Lobby”, users can learn about the Company’s global legacy. The other virtual rooms include the “Pink Plaza” which explores the Company’s values and the “Innovation Center” that presents Mary Kay’s innovative skin care products and showcases key product benefits and ingredients. The platform also allows users to add their favorite Mary Kay products to a Wishlist to be shared with the user’s Independent Beauty Consultant.
“The launch of Suite 13TM is the result of months of creativity, passion and commitment to provide Mary Kay’s Independent Beauty Consultants the best and most innovative tools in the market to help them manage their business,” says Sheryl Adkins-Green, Chief Marketing Officer for Mary Kay Inc. “Today, technology is at the center of everything, and people – especially the younger generation - want to discover, learn and find out about new products online. Suite 13TM will provide Mary Kay Independent Beauty Consultants the flexibility of a digital business by being able to introduce our Mary Kay brand everywhere at any time and to elevate the way they build relationships with their customers by sharing an immersive beauty experience. To win in this new digital-driven environment, we will continue to find new ways for people to connect virtually for personalized low-touch experiences based in high-tech innovation.”
For the design of Suite 13 TM, Mary Kay partnered with Obsess, a leading experiential e-commerce platform that enables brands to create interactive, online virtual experiences using virtual reality. Led by female entrepreneur Neha Singh, Obsess has worked with other global beauty and fashion brands creating memorable, branded virtual experiences for consumers. In keeping with its mission to empower women’s lives, Mary Kay also partnered with several female photographers to produce the images displayed in the virtual platform.
“Suite 13 TM is about bringing the Mary Kay beauty experience together in a much more accessible way to independent beauty consultants and their customers where they already are,” said Neha Singh, founder and CEO of Obsess. “With Suite 13TM, the Mary Kay team took care of every detail of the platform, giving you the feeling of being in a Mary Kay virtual showroom without having to actually be physically present. Our platform has allowed brands to create visually appealing, immersive virtual experiences that are changing the way they engage with their customers and we are excited for Mary Kay customers to continue to discover, learn and interact with the brand in a new digital environment.”
Suite 13 TM was initially launched in Mexico earlier in 2021, followed by Brazil, Argentina, Spain, Colombia and Peru. The Company expects to launch the platform in most of its markets by the end of 2021. Mary Kay is the first company to launch this type of virtual experience in its industry. Suite 13 TM is only the latest technological innovation by Mary Kay and its Mary Kay Global Design Studio. Mary Kay launched the Mary Kay® Skin Analyzer, an app that leverages the most advanced and scientifically-based Artificial Intelligence facial skin recommendation technology to help Independent Beauty Consultants provide a customized skin care regimen of Mary Kay products with just a quick skin scan. Another innovation, Mary Kay® MirrorMe™ Web, provides customers a virtual way to “try-before-you-buy,” directly from an Independent Beauty Consultant’s Website using virtual reality technology. MirrorMe™ is also available for iOS and Android devices.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005306/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom